by Stacey Hawkins | Feb 10, 2020 | Immunotherapies
The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—Kymriah (Novartis; Basel, Switzerland) and Yescarta—(Gilead; Foster City, CA) were approved in 2017, and remain one of the hottest immunotherapies on the market today. They work by...
by Stacey Hawkins | Sep 7, 2017 | Immunotherapies
THE FLASH OF THE FIRST CAR-T Last week’s much anticipated FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphocytic leukemia hails as the first gene therapy on the US market. Classified as a “cell-based gene therapy,” Novartis’...
by Stacey Hawkins | Jan 19, 2017 | Immunotherapies
Understanding CAR-T Safety Chimeric antigen receptor therapy (CAR-T) is our top technology pick of 2016, blazing trails in drug development with its innovative approach of using engineered immune cells to fight cancer. Despite its success in clinical trials, safety...
by Stacey Hawkins | May 19, 2016 | Uncategorized
BIOPHARMA’S DARLING Immunotherapy is the current biopharma darling, garnering massive investment and media attention. Ranging from monoclonal antibodies to engineered T-cells, companies are rapidly learning how to harness the power of the immune system to fight...